DaVita Gestion

Gestion contrôle des critères 3/4

Le PDG DaVita est Javier Rodriguez, nommé en Jun2019, a un mandat de 5.42 ans. La rémunération annuelle totale est $ 6.71M, composée du salaire de 21% et des bonus 79%, y compris les actions et options de la société. détient directement 1.02% des actions de la société, d'une valeur de $ 138.67M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 5.1 ans et 4.3 ans.

Informations clés

Javier Rodriguez

Directeur général

US$6.7m

Rémunération totale

Pourcentage du salaire du PDG	21.0%
Durée du mandat du directeur général	5.4yrs
Propriété du PDG	1.0%
Durée moyenne d'occupation des postes de direction	5.1yrs
Durée moyenne du mandat des membres du conseil d'administration	4.3yrs

Mises à jour récentes de la gestion

Recent updates

An Intrinsic Calculation For DaVita Inc. (NYSE:DVA) Suggests It's 47% Undervalued

Sep 16

DaVita Inc.'s (NYSE:DVA) Shares Lagging The Market But So Is The Business

Sep 01

DaVita (NYSE:DVA) Has A Pretty Healthy Balance Sheet

Jul 02

Is There Now An Opportunity In DaVita Inc. (NYSE:DVA)?

Jun 19

Are DaVita Inc. (NYSE:DVA) Investors Paying Above The Intrinsic Value?

Jun 04

Returns On Capital At DaVita (NYSE:DVA) Have Hit The Brakes

May 22

DaVita Stock Is A Hold As It Expands In Latin America

Mar 18

Market Might Still Lack Some Conviction On DaVita Inc. (NYSE:DVA) Even After 27% Share Price Boost

Mar 13

Is There Now An Opportunity In DaVita Inc. (NYSE:DVA)?

Mar 04

DaVita Inc. (NYSE:DVA) Analysts Are Pretty Bullish On The Stock After Recent Results

Feb 16

Is DaVita (NYSE:DVA) Using Too Much Debt?

Feb 08

DaVita: Assessing After The Rally

Dec 29

DaVita Inc.'s (NYSE:DVA) Subdued P/E Might Signal An Opportunity

Dec 24

DaVita (NYSE:DVA) Has A Somewhat Strained Balance Sheet

Nov 08

DaVita: Simple And Compelling After Sell-Off

Oct 26

Returns On Capital Signal Difficult Times Ahead For DaVita (NYSE:DVA)

Oct 25

DaVita: Continued Economic Hurdles, Market Expectations May Be Correct

Oct 05

Is It Too Late To Consider Buying DaVita Inc. (NYSE:DVA)?

Aug 14

DaVita (NYSE:DVA) Takes On Some Risk With Its Use Of Debt

Jul 31

DaVita: Breakout Not Supported Without Leverage Effects, Reiterate Hold

Jul 21

Returns At DaVita (NYSE:DVA) Appear To Be Weighed Down

Jul 18

DaVita Inc. (NYSE:DVA) Shares Could Be 41% Below Their Intrinsic Value Estimate

Jul 03

What Is DaVita Inc.'s (NYSE:DVA) Share Price Doing?

May 01

These 4 Measures Indicate That DaVita (NYSE:DVA) Is Using Debt Extensively

Apr 17

Investors Met With Slowing Returns on Capital At DaVita (NYSE:DVA)

Apr 03

Are Investors Undervaluing DaVita Inc. (NYSE:DVA) By 40%?

Mar 08

DaVita HealthCare Partners Q4 2022 Earnings Preview

Feb 21

Moon Capital - DaVita: A Recession-Resistant Cash Generating Machine

Feb 08

Is Now The Time To Look At Buying DaVita Inc. (NYSE:DVA)?

Jan 24

Is DaVita (NYSE:DVA) A Risky Investment?

Jan 09

DaVita: Shares Still Appear Cheap After Outlook Cut, Technicals Suggest Caution

Dec 12

DaVita Q3 2022 Earnings Preview

Oct 27

Is Now The Time To Look At Buying DaVita Inc. (NYSE:DVA)?

Oct 18

Analyse de la rémunération des PDG

Comment la rémunération de Javier Rodriguez a-t-elle évolué par rapport aux bénéfices de DaVita?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2024	n/a	n/a	US$828m
Jun 30 2024	n/a	n/a	US$860m
Mar 31 2024	n/a	n/a	US$816m
Dec 31 2023	US$7m	US$1m	US$692m
Sep 30 2023	n/a	n/a	US$596m
Jun 30 2023	n/a	n/a	US$454m
Mar 31 2023	n/a	n/a	US$500m
Dec 31 2022	US$3m	US$1m	US$547m
Sep 30 2022	n/a	n/a	US$680m
Jun 30 2022	n/a	n/a	US$834m
Mar 31 2022	n/a	n/a	US$903m
Dec 31 2021	US$3m	US$1m	US$978m
Sep 30 2021	n/a	n/a	US$984m
Jun 30 2021	n/a	n/a	US$883m
Mar 31 2021	n/a	n/a	US$791m
Dec 31 2020	US$73m	US$1m	US$783m
Sep 30 2020	n/a	n/a	US$832m
Jun 30 2020	n/a	n/a	US$824m
Mar 31 2020	n/a	n/a	US$816m
Dec 31 2019	US$17m	US$1m	US$705m
Sep 30 2019	n/a	n/a	US$623m
Jun 30 2019	n/a	n/a	US$548m
Mar 31 2019	n/a	n/a	US$551m
Dec 31 2018	US$8m	US$900k	US$616m
Sep 30 2018	n/a	n/a	US$617m
Jun 30 2018	n/a	n/a	US$698m
Mar 31 2018	n/a	n/a	US$652m
Dec 31 2017	US$8m	US$900k	US$909m

Rémunération vs marché: La rémunération totale de Javier ($USD 6.71M ) est inférieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 12.67M ).

Rémunération et revenus: La rémunération de Javier a augmenté de plus de 20 % au cours de l'année écoulée.

PDG

Javier Rodriguez (53 yo)

5.4yrs

Titularisation

US$6,712,328

Compensation

Mr. Javier J. Rodriguez serves as an Independent Director at Gilead Sciences, Inc. since June 15, 2020. He has been Chief Executive Officer and Executive Director of DaVita Inc. since June 1, 2019. Mr. Rod...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Javier Rodriguez	CEO & Executive Director	5.4yrs	US$6.71m	1.02% $ 138.7m
Joel Ackerman	CFO & Treasurer	7.8yrs	US$6.87m	0.11% $ 15.4m
Kathleen Waters	Chief Legal & Public Affairs Officer	8.5yrs	US$5.61m	0.071% $ 9.6m
James Hearty	Chief Compliance Officer	6.7yrs	US$2.73m	0.015% $ 2.0m
David Maughan	Chief Operating Officer	less than a year	pas de données	0.0073% $ 996.2k
Christopher Berry	Group VP & Chief Accounting Officer	1.3yrs	pas de données	pas de données
Madhu Narasimhan	Chief Information Officer	less than a year	pas de données	pas de données
Nic Eliason	Group Vice President of Investor Relations	no data	pas de données	pas de données
Jessica Hergenreter	Chief People Officer	less than a year	pas de données	pas de données
Misha Palecek	Chief Transformation Officer of U.S. Kidney Care Business	no data	pas de données	pas de données
Jeffrey Giullian	Chief Medical Officer of Kidney Care	4.8yrs	pas de données	pas de données
Partha Das	Chief Medical Officer of DaVita International	6.3yrs	pas de données	pas de données

5.1yrs

Durée moyenne de l'emploi

55yo

Âge moyen

Gestion expérimentée: L'équipe dirigeante de DVA est chevronnée et expérimentée (5.1 années d'ancienneté moyenne).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Javier Rodriguez	CEO & Executive Director	5.4yrs	US$6.71m	1.02% $ 138.7m
Charles Berg	Director	17.7yrs	US$322.46k	0.032% $ 4.4m
Barbara Desoer	Independent Director	9.1yrs	US$384.96k	0.015% $ 2.0m
Phyllis Yale	Independent Director	8.3yrs	US$374.96k	0.020% $ 2.6m
Wendy Schoppert	Independent Director	1.3yrs	US$106.86k	0.0022% $ 302.7k
Pamela Arway	Independent Chair	15.5yrs	US$497.46k	0.030% $ 4.1m
Dennis Pullin	Independent Director	less than a year	pas de données	0.00075% $ 101.8k
Adam Schechter	Independent Director	2.2yrs	US$334.96k	0.0044% $ 601.2k
Jason Hollar	Independent Director	2.5yrs	US$364.96k	0.0055% $ 751.9k
Gregory Moore	Independent Director	3.2yrs	US$355.89k	0.0070% $ 952.7k

4.3yrs

Durée moyenne de l'emploi

61.5yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de DVA sont considérés comme expérimentés (ancienneté moyenne 4.3 ans).

DaVita Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

DaVita Appoints Jessica Hergenreter as Chief People Officer

CEO & Executive Director recently sold US$9.9m worth of stock

DaVita Announces Executive Appointments, Effective September 15, 2024

CEO & Executive Director recently sold US$6.3m worth of stock

Chief Legal & Public Affairs Officer recently sold US$1.1m worth of stock

Chief Legal & Public Affairs Officer notifies of intention to sell stock

Recent updates

DaVita: Better Results Than Fresenius, But A 'Hold' Due To Valuation

Is DaVita Inc. (NYSE:DVA) Potentially Undervalued?

Third quarter 2024 earnings: EPS misses analyst expectations

Is DaVita (NYSE:DVA) A Risky Investment?

DaVita Appoints Jessica Hergenreter as Chief People Officer

DaVita Inc. to Report Q3, 2024 Results on Oct 29, 2024

CEO & Executive Director recently sold US$9.9m worth of stock

An Intrinsic Calculation For DaVita Inc. (NYSE:DVA) Suggests It's 47% Undervalued

DaVita Announces Executive Appointments, Effective September 15, 2024

DaVita Inc.'s (NYSE:DVA) Shares Lagging The Market But So Is The Business

CEO & Executive Director recently sold US$6.3m worth of stock

New major risk - Revenue and earnings growth

Chief Legal & Public Affairs Officer recently sold US$1.1m worth of stock

Chief Legal & Public Affairs Officer notifies of intention to sell stock

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Now 21% overvalued

DaVita Inc. to Report Q2, 2024 Results on Aug 06, 2024

Now 20% overvalued after recent price rise

DaVita (NYSE:DVA) Has A Pretty Healthy Balance Sheet

Now 19% overvalued after recent price rise

Now 21% overvalued after recent price rise

Is There Now An Opportunity In DaVita Inc. (NYSE:DVA)?

Now 22% overvalued after recent price rise

Are DaVita Inc. (NYSE:DVA) Investors Paying Above The Intrinsic Value?

Now 21% overvalued after recent price rise

Returns On Capital At DaVita (NYSE:DVA) Have Hit The Brakes

Independent Director recently sold US$698k worth of stock

DaVita Appoints Madhu Narasimhan as Chief Information Officer, Effective June 3, 2024

Independent Director notifies of intention to sell stock

Price target increased by 9.0% to US$140

High number of new directors

DaVita Inc., Annual General Meeting, Jun 06, 2024

DaVita Inc. to Report Q1, 2024 Results on May 02, 2024

Davita Announces Dennis Pullin to Its Board of Directors

DaVita Stock Is A Hold As It Expands In Latin America

Chief Operating Officer of Kidney Care exercised options and sold US$3.0m worth of stock

Market Might Still Lack Some Conviction On DaVita Inc. (NYSE:DVA) Even After 27% Share Price Boost

CEO & Executive Director exercised options and sold US$36m worth of stock

Price target increased by 7.4% to US$131

Is There Now An Opportunity In DaVita Inc. (NYSE:DVA)?

Chief Compliance Officer recently sold US$3.0m worth of stock

Chief Compliance Officer notifies of intention to sell stock

DaVita Inc. (NYSE:DVA) Analysts Are Pretty Bullish On The Stock After Recent Results

Price target increased by 14% to US$120

Is DaVita (NYSE:DVA) Using Too Much Debt?

DaVita Inc. to Report Q4, 2023 Results on Feb 13, 2024

DaVita: Assessing After The Rally

DaVita Inc.'s (NYSE:DVA) Subdued P/E Might Signal An Opportunity

CEO & Executive Director exercised options and sold US$16m worth of stock

Investor sentiment improves as stock rises 15%

Consensus EPS estimates increase by 13%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

DaVita (NYSE:DVA) Has A Somewhat Strained Balance Sheet

DaVita: Simple And Compelling After Sell-Off

Returns On Capital Signal Difficult Times Ahead For DaVita (NYSE:DVA)

DaVita Inc. to Report Q3, 2023 Results on Nov 07, 2023

Investor sentiment deteriorates as stock falls 19%

DaVita: Continued Economic Hurdles, Market Expectations May Be Correct

Chief Legal & Public Affairs Officer notifies of intention to sell stock

Is It Too Late To Consider Buying DaVita Inc. (NYSE:DVA)?

Price target increased by 7.3% to US$113

New major risk - Financial position

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

DaVita (NYSE:DVA) Takes On Some Risk With Its Use Of Debt

DaVita Inc. Announces Management Changes

DaVita: Breakout Not Supported Without Leverage Effects, Reiterate Hold

Returns At DaVita (NYSE:DVA) Appear To Be Weighed Down

DaVita Inc. to Report Q2, 2023 Results on Aug 03, 2023

DaVita Inc. (NYSE:DVA) Shares Could Be 41% Below Their Intrinsic Value Estimate